A new report details persistent disparities in cancer care, and the FDA approved an antibody-drug conjugate as a first-line treatment for advanced triple-negative breast cancer.
At the AACR Annual Meeting 2026, a session highlighted progress from four Cancer Grand Challenges teams on the interplay of mutations, promoting factors, and tissue-specific epigenetic programs in cancer development and on the biology...
The AACR Cancer Disparities Progress Report 2026 included an examination of the growing gap in cancer care between rural and urban areas. The report also featured the stories of several cancer survivors—including Dennis Gruenhagen,...
Sacituzumab govitecan-hziy was approved as a monotherapy or in combination with pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for two indications in adult patients with unresectable locally advanced...
Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration (FDA) has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), with or without pertuzumab (Perjeta),...
The cochairs of the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers—Andrew Futreal, PhD, FAACR, of The University of Texas MD Anderson Cancer Center; Taran Gujral, PhD, of Fred Hutch...
Afamitresgene autoleucel was granted full approval with an expanded indication for certain adult and pediatric patients with advanced synovial sarcoma. The U.S. Food and Drug Administration (FDA) has granted full approval to afamitresgene autoleucel...
Scientists seek to understand relationship between viral infections and cancer recurrence, and breast cancer survivors seek menopause-symptom relief.
Can AI agents do cancer research? Many AI-centric research teams currently believe that with the right training, AI agents can in fact rise to the level of “co-scientists,” including Jure Leskovec, PhD, of Stanford...
Chenia Lloyd-Gascho, who was diagnosed with Li-Fraumeni syndrome when he was 8 years old, shared what it is like to grow up knowing you will one day get cancer, the routine monitoring recommended to...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More